Search results for: Pricing and Reimbursement
Filter search results
OHE at ISPOR Europe: Posters
13 November 2014
…Sussex, Dyfrig Hughes (Bangor University) and Nancy Devlin Ispor are uk_systems_innovation_compatible_ac from Office of Health Economics Amanda Chapman, C. A. Taylor (University of Birmingham) and A. J. Girling (University…
Do Respondents Completing Abstract, Hypothetical Priority-Setting Exercises Agree with the Policy Implications of Their Choices?
3 March 2015
…scenarios involving hypothetical patients and medical conditions. In order to minimise bias, researchers usually present the scenarios in an abstract manner and provide limited descriptive information. This has led to…
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
25 August 2015
…does not account for drug life cycle pricing, i.e. the evolution of a drug price throughout its life. In reality, the drug launch price (which is considered in cost-effectiveness analyses)…
Eliciting the Relative Value of Life Extension at the End of Life
29 November 2016
…OHE’s Koonal Shah provided a critique and discussion. Koonal set out the strengths and limitations of the Q methodology approach, and described how Rachel’s study fits within the existing empirical…
The Office of Health Economics Becomes a Registered Charity
3 February 2017
…to serve the public interest by providing research and analysis that will increase understanding of health, health care and biomedical research issues and public policy challenges. OHE’s new status as…
Is There Societal Support for an End of Life Premium?
8 May 2017
…to address some of the limitations and ambiguities in the earlier research on this topic. Koonal highlighted three innovative studies led by researchers in the Netherlands, Denmark and Scotland. The…
New OHE Seminar Briefing: Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
11 August 2017
…pricing is not free; consumers with dementia and cognitive impairment are not be full informed; supply is constrained; and the system is fragmented. However, the US is beginning to embrace…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
7 September 2018
…financialisation and the obligation to maximise shareholder value through profit, the pharmaceutical sector is increasingly under pressure to deliver short-term financial returns through raising drug prices and executing share buybacks…
OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
4 October 2018
…will be hosting two lunchtime seminars this month. OHE Lunchtime Seminar with Steven Pearson on ‘Early experience with HTA of gene therapies in the US: pricing and paying for cures’….